Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 9/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.38 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | KMO | O15229 | 1/20 | 0.37 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.37 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21610150 | 1.00 | KDR (0.41) | KDRAAK1ADORA3TAS1R3TAS1R1 | |
| SCHEMBL21580658 | 0.84 | RIOK2 (0.45) | KDRAAK1ADORA3TAS1R3TAS1R1 | |
| SCHEMBL21611233 | 0.84 | KDR (0.42) | KDRMETKMOGRM4PTK2 | |
| SCHEMBL21610134 | 0.84 | ADORA3 (0.44) | AAK1ADORA3TAS1R3TAS1R1MAPT | |
| SCHEMBL21610137 | 0.84 | ADORA3 (0.44) | AAK1ADORA3TAS1R3TAS1R1MAPT | |
| SCHEMBL20906310 | 0.82 | AAK1 (0.48) | AAK1MAPT | |
| SCHEMBL21610277 | 0.82 | RAF1 (0.47) | KDRAAK1ADORA3 | |
| SCHEMBL1983127 | 0.82 | AAK1 (0.48) | AAK1MAPT | |
| SCHEMBL21610275 | 0.82 | RAF1 (0.47) | KDRAAK1ADORA3 | |
| SCHEMBL1978742 | 0.82 | AAK1 (0.48) | AAK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3947365-B1 | SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF | BIONOMICS LTD (AU) | 2025-10-01 | — | — | EP | disclosed |
| US-12139473-B2 | Substituted-N-heteroaryl compounds and uses thereof | BIONOMICS LIMITED (AU) | 2024-11-12 | — | — | US | disclosed |
| US-20220112176-A1 | SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2022-04-14 | — | — | US | disclosed |
| US-20220112176-A1 | SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2022-04-14 | — | — | US | disclosed |
| EP-3947365-A2 | SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF | Bionomics Limited (AU) | 2022-02-09 | — | — | EP | disclosed |
| WO-2020000065-A2 | SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2020-01-02 | — | — | WO | disclosed |
| WO-2020000065-A2 | SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2020-01-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220112176-A1 | SUBSTITUTED-N-HETEROARYL COMPOUNDS AND USES THEREOF | GABRE, GRIN2C, GRIN2A | KDR 4670/4885AAK1 2592/4885ADORA3 1506/4885 |
| US-12139473-B2 | Substituted-N-heteroaryl compounds and uses thereof | SCN3A, KCND3, GRIN3A | KDR 4056/4885AAK1 610/4885ADORA3 648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.